Novartis (NVS) stock dropped 3% after pelacarsen failed its cardiovascular outcomes trial, raising concerns about ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results